长链非编码RNA-重编码调控因子与肿瘤的研究进展

长链非编码RNA(LncRNA)是一类长度超过200核苷酸且不编码蛋白质的RNA分子。肿瘤基因组学的快速发展使LncRNA在人类肿瘤研究方面的功能更加显著。基因间LncRNA(LincRNA)-重编码调控因子(ROR)作为一种新型LncRNA,其作用机制在结直肠癌、胰腺癌、乳腺癌的发生发展过程中有报道。我们就LincRNA-ROR在肿瘤中的相关调控机制以及在不同肿瘤中的研究现状做简要综述,以便对其有进一步了解。     

长非编码RNA作为ceRNA分子在乳腺癌中的调控机制

乳腺癌是全球女性最常见的异质性恶性肿瘤，分为多种亚型，不同亚型的临床治疗方式和效果不同。多项研究表明长非编码RNA(lncRNA)在乳腺癌的进展中起着关键作用，其中由lncRNA-miRNA-mRNA相互作用形成的ceRNA网络是RNA分子间的一种新调节机制。LncRNA通过该网络广泛参与乳腺癌的增殖、迁移、凋亡等多种生物学过程，可作为诊断和治疗的分子靶点。该文重点阐述了lncRNA介导的ceRNA调控机制，系统总结了lncRNA相关ceRNA网络在调控不同乳腺癌亚型的增殖、迁移和耐药性中的研究进展，旨在为乳腺癌的精准治疗和lncRNA研究提供新见解。     

长非编码RNA与重大临床疾病

以往,人们对细胞和机体的生长发育及疾病发病机制的研究往往集中于蛋白质及其编码基因。近年来在通过对蛋白编码基因表观遗传水平、转录水平以及转录后水平的研究,越来越多的证据显示长非编码RNA(long noncoding RNA,LncRNA)在生长、发育以及疾病的发生发展中起重要的作用。人体基因组中约98%的基因转录组为非编码RNA,其中绝大部分为LncRNA,只有不足2%的编码基因最终经过转录翻译为蛋白质。最新的研究表明,人体中存在数万条LncRNA。目前,只有极少数LncRNA在细胞代谢及疾病发生中的作用被初步揭示,绝大部分的LncRNA的功能完全未知。进一步深入研究LncRNA的生物学功能,有可能为阐明许多重大疾病的发病过程及机制带来重大的突破,并提供独特的干预靶点。本综述简要讨论LncRNA与一些重大临床疾病关系的最新研究进展。     

长链非编码RNA与性激素依赖性肿瘤

随着基因测序技术与核酸定量分析技术的发展,近年的大量研究表明,长链非编码RNA (long non-coding RNA,LncRNA) 通过多种途径调控基因表达,具有调节细胞功能的重要作用。LncRNA的异常表达与肿瘤发生发展之间的联系被广泛关注。其中,关于LncRNA与3种最常见的性激素依赖性肿瘤乳腺癌、子宫内膜癌和前列腺癌的研究,揭示其在肿瘤细胞或组织中扮演着类似于原癌基因或抑癌基因的双重角色。并通过多种调控机制,参与癌细胞的侵袭、增殖、转移等过程。因性激素受体分布的特异性,使得与之相关的多种LncRNA的表达也具有较高的特异性。本文总结LncRNA与乳腺癌、子宫内膜癌和前列腺癌的相关研究进展,包括涉及到的LncRNA种类、表达差异、作用机制及作为生物标志物或治疗靶点的可行性评价。     

长链非编码RNA在乳腺癌中的研究进展

乳腺癌(breast cancer)是全世界女性中常见的恶性肿瘤,也是女性癌症死亡的主要原因之一。长链非编码RNA (lncRNAs)过去被认为是"垃圾",而越来越多的证据表明,其在乳腺癌的发生发展中起着关键作用。该文就lncRNAs的功能以及在乳腺癌诊断和治疗中的作用进行综述。     

长非编码RNA与糖尿病及其并发症

2型糖尿病是一种严重威胁人类健康的慢性非传染性代谢疾病,而胰岛素抵抗和胰岛β细胞功能衰竭被认为是其主要致病原因。在以往对糖尿病及其并发症发病机制的研究中,往往关注传统的蛋白编码基因(mRNA)。长链非编码RNA(long noncoding RNA,LncRNA)是一类长度大于200bp,不编码蛋白的RNA分子。近年来,越来越多的研究发现LncRNA在表观遗传、转录及转录后水平等多个层面上参与调控基因表达及代谢过程。本综述旨在讨论LncRNA在糖脂代谢调控、糖尿病及糖尿病并发症发生中作用的最新研究进展。     

LncRNA的结构、功能及其与疾病的关系

70%的人类基因组能够被转录,而其中仅有1%～2%的转录本能够编码蛋白,余下98%均为非编码RNA（non-coding RNA,ncRNA）.在ncRNA中,长度大于200核苷酸称为长链非编码RNA（long non-coding RNA,LncRNA）,占全部ncRNA的80%～90%．LncRNA除了数量庞大以外,还具有表达量较低、物种间保守性较差及细胞表达特异性等特点,使LncRNA结构及作用机制等研究充满挑战．目前关于LncRNA的研究主要集中于功能方面．LncRNA能够广泛参与生物体的各种生理及病理过程,如表观遗传学调控、癌症、神经系统功能等．LncRNA作用机制众多,能够以分子诱饵、分子向导、分子支架及信号通路的调节剂等多种角色参与调节机体各种生物学过程．解析LncRNA的分子结构、深入研究其在生物体生理及病理过程中所发挥的作用,并揭示其作用机制,不仅能够加深对生物体生理及病理过程的认识,同时也能给某些疾病的诊断、防治提供新的思路及解决途径．本文综述了近年来有关LncRNA结构、功能及作用机制相关研究进展,以期为后续LncRNA相关研究提供参考.     

长链非编码RNA与糖尿病及其并发症的关系

长链非编码RNA(long non-coding RNA,LncRNA)是不编码蛋白质RNA的一种,它的长度一般超过200bp。最初这些LncRNA未发现有生物学功能,而被认为是基因转录的“噪音”,但越来越多的研究表明LncRNA是一类新的功能性RNA,可以通过与蛋白质、染色质和其他RNA的相互作用来调节人体多种生物功能。糖尿病是一种以慢性高血糖为主要特征的代谢性疾病,并且糖尿病并发症较多,严重威胁着人类的健康。近年来的研究显示LncRNA参与糖尿病的病理过程,与糖尿病并发症的发生密切相关。本文主要探究LncRNA与糖尿病及其并发症的关系,为糖尿病的研究和治疗提供理论依据。     

LncRNA在糖尿病及其并发症中的作用

长链非编码RNA(long non-coding RNA,LncRNA)是一类转录本长度超过200个核苷酸、无蛋白质编码功能的RNA分子,起初认为它是转录过程中的副产物,无生物学功能。随着研究的不断推进,人们发现LncRNA不但在细胞增殖、分化和代谢中发挥重要的调节作用,而且还参与癌症、糖尿病、神经退行性疾病的病理进程。本文主要就LncRNA在糖尿病及其并发症中的作用作一综述。     

Clinical Breast Examination As the Recommended Breast Cancer Screening Modality in a Rural Community in Malaysia; What Are the Factors That Could Enhance Its Uptake?

Breast cancer is the most common cause of deaths and the most frequently diagnosed cancer among women worldwide. This study aimed to determine the prevalence of breast cancer screening, specifically on clinical breast examination, and the predictors of its uptake among women in Malaysia. A cross-sectional study was carried out in five selected districts whereby women aged between 20 to 64 years old, from a total of 1000 households were interviewed. A total of 1192 women responded to the survey of which 53.3% reported had ever done clinical breast examination. Significant associations with clinical breast examination were noted for income and distance from the hospital. These factors should be considered in developing interventions aimed at promoting clinical breast examination. In particular, healthcare providers should be proactive in raising awareness about clinical breast examination among women in Malaysia.     

Sexual functioning in young women in the context of breast cancer treatment

Breast cancer is the most common type of cancer among women worldwide. The number of breast cancer survivors has been growing because of earlier detection and improved treatment. Young women under 50 years of age account for relatively small percentage of all newly diagnosed breast cancer patients. However, their medical and psychosocial context of the disease is unique. Breast cancer is diagnosed at the most productive time in life. Concerns about childbearing, partner rejection, sexual function, body image, sexual attractiveness and career are common. For all these reasons experience of breast cancer diagnosis and treatment among young women requires special attention. Researches indicate that oncological treatment may negatively affect female sexual functioning. Chemotherapy is one of the greatest risk factors of sexual dysfunctions, especially when it results in medication-induced menopause. The duration and severity of sexual problems depend on a wide variety of factors: medical, psychological and interpersonal. These side effects may last for many years after the end of treatment. It is known that breast cancer affects both patients and their partners. The first sexual experience after surgery may be a turning point in sexual adaptation in couples. Communication is crucial in this process. More knowledge about sexual difficulties and sexual adaptation process of young breast cancer survivors (YBCSs) and their partners is needed. Knowing protective and risk factors is necessary to identify couples at risk for sexual dysfunctions in order to professionally support them in the best way and at the right time.     

A follow-up study of 105 women with breast cancer following reduction mammaplasty.

Reduction mammaplasty is one of the most common procedures performed by plastic surgeons in Canada. In a recent study of 27,500 women in the province of Ontario who underwent breast reduction surgery, 105 women were identified who developed breast cancer after reduction mammaplasty. The purpose of this study was to compare women who had breast cancer and had a previous breast reduction with women who had breast cancer but did not have a breast reduction. Specifically, we wanted to document patient demographics, cancer type, surgical and nonsurgical treatment, and eventual outcome. A comparison group of non-breast reduction women was taken from the cohort of breast cancer patients in the province of Ontario, and the two groups were matched for age, year of diagnosis, and place of diagnosis. It was found that (1) the average age at diagnosis of breast cancer is significantly younger for women who have had previous breast reduction surgery than for those who have not; (2) the median interval between breast reduction and cancer is 5 years; (3) the type, location, and side of breast cancers are similar in the two groups of women; (4) breast reduction does not significantly increase or decrease survival rate from breast cancer; and (5) women who have had breast reduction receive the same treatment for their breast cancer as women who have not had reduction mammaplasty.     

Fertility preservation and preimplantation genetic assessment for women with breast cancer

Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child.     

Can modulation of mammary gland development by dietary factors support breast cancer prevention?

Breast cancer continues to be a major challenge for public health, since it is the most common cancer of women in the Western world, and its prevalence is still increasing. In order to achieve better results in the prevention and treatment of breast cancer it is crucial to identify the mechanisms behind its initiation, i.e. the changes and deviations that have occurred in the mammary gland growth. It has long been known that a woman's reproductive history is the strongest breast cancer risk factor if genetic background and age are excluded. The reproductive hormones, and the timing of events leading to changes in these hormones, and consequently, in the mammary gland, are the most important players. However, it has become obvious that dietary components may also contribute to breast cancer risk through their effects on the mammary gland. The past few years have added important information to our knowledge of the mechanisms behind breast cancer initiation at the level of target cells (mammary stem cells) and gene expression (genetic 'fingerprint' associated with persistent pregnancy-induced protection against breast cancer), as well as of the effects of certain dietary factors (steroid action modulators). These results and their links to breast cancer initiation and progression will be discussed.     

乳腺癌化疗现状及相关研究进展

乳腺癌是除非上皮来源肿瘤中女性最常见的恶性肿瘤,在美国平均每3名女性中就有一名患乳腺癌,是女性肿瘤致死中的第二大原因,给政府经济造成了很大的损失。目前,乳腺癌主要是以手术治疗为主,而化疗,放疗等也作为相当重要的辅助治疗应用于临床。这种手术加化疗的治疗方法一直可以取得很好的疗效,甚至于可以保住乳房。近年来,乳腺癌的化疗已逐步成为其治疗的首选方式,包括术后辅助化疗和术前的新辅助化疗。但由于化疗药物的滥用和肿瘤本身的异质性或是其他原因,越来越多的肿瘤耐药性报道给乳腺癌的化疗带来了很大的挑战。而这种肿瘤耐药性的分子机制尚不是很清楚。本文将从乳腺癌的概述,乳腺癌化疗的现状及乳腺癌化疗的前景来综述这一灾难性疾病。     

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis

Introduction

Breast cancer is the most common female cancer and the second most common cause of female cancer-related deaths in the United States. World-wide, more than one million women will be diagnosed with breast cancer annually. In 2007, more than 175,000 women were diagnosed with breast cancer in the United States. However, deaths due to breast cancer have decreased in the recent years in part because of improved screening techniques, surgical interventions, understanding of the pathogenesis of the disease, and utilization of traditional chemotherapies in a more efficacious manner. One of the more exciting areas of improvement in the treatment of breast cancer is the entrance of novel therapies now available to oncologists. In the field of cancer therapeutics, the area of targeted and biologic therapies has been progressing at a rapid rate, particularly in the treatment of breast cancer. Since the advent of imatinib for the successful treatment of chronic myelogenous leukemia in the 2001, clinicians have been searching for comparable therapies that could be as efficacious and as tolerable. In order for targeted therapies to be effective, the agent must be able to inhibit critical regulatory pathways which promote tumor cell growth and proliferation. The targets must be identifiable, quantifiable and capable of being interrupted. In the field of breast cancer, two advances in targeted therapy have led to great strides in the understanding and treatment of breast cancer, namely hormonal therapy for estrogen positive receptor breast cancer and antibodies directed towards the inhibition of human epidermal growth factor receptor (HER)2. These advances have revolutionized the understanding and the treatment strategies for breast cancer. Building upon these successes, a host of novel agents are currently being investigated and used in clinical trials that will hopefully prove to be as fruitful. This review will focus on novel therapies in the field of breast cancer with a focus on metastatic breast cancer (MBC) and updates from the recent annual ASCO meeting and contains a summary of the results.     

核酸适配体在三阴性乳腺癌诊疗中的研究进展*

乳腺癌是女性高发恶性肿瘤,三阴性乳腺癌(triple-negative breast cancer, TNBC)恶性程度极高,且发病机制复杂,是乳腺癌分型中预后最差的类型,但目前其早期筛查和诊断的敏感度仍处在较低水平。因此,亟须通过应用具有高度特异性的肿瘤标志物分子探针,实现其早期诊断和治疗。核酸适配体是在人工合成的随机单链核酸序列文库中,通过指数富集的配体系统进化技术(systematic evolution of ligands by exponential enrichment, SELEX)筛选获得的寡核苷酸序列。高效的分子识别能力使其成为最具潜力的生物靶向分子,在肿瘤诊断及治疗中具有广阔的应用前景。目前,通过筛选已获得了多种靶向TNBC细胞的核酸适配体。重点综述基于SELEX及其衍生技术筛选TNBC相关核酸适配体的新进展,以及核酸适配体在TNBC诊断和治疗中的应用,为相关研究提供参考。